Even though a generally accepted opinion is present about conservative management for type 1 and type 2 acromioclavicular dislocation and surgical management for type 4 to type 6 dislocations, different opinions come under play for conservative versus surgical management in cases with acute type 3 acromioclavicular joint dislocation. We came across 20 cases of type 3 AC joint dislocation with a varied age profile (range 18 to 50 years, mean 34.4±6.5 years). Patients usually complain of pain and swelling and difficulty in moving shoulder joint. The diagnosis can be confirmed by radiographs which shows widening of AC joint >2-4 mm and coracoclavicular distance >5 mm and superior displacement of distal clavicle. In our series, we have treated them with modified Weaver Dunn technique. Immobilized arm in arm pouch for 3 weeks and follow up was done to assess functional outcome. In this study we present the outcome and related complications with modified Weaver Dunn technique for type 3 acromioclavicular joint dislocation.
Ebstein's anomaly is a rare congenital heart disease characterized by downward displacement of the tricuspid valve, atrialization of right ventricle, enlarged right atrium with tricuspid regurgitation, or stenosis. It is often associated with atrial septal defect (ASD) or patent foramen ovale with right to left shunt. It has a varied clinical presentation and can manifest as cyanosis, ventricular, or supraventricular arrhythmias and recurrent episodes of congestive heart failure. We describe the anesthetic management of a female patient with Ebstein's anomaly who had right frontal lobe abscess due to paradoxical embolism for decompressive craniotomy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.